Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM).

ABSTRACT:

Background

Daily primaquine-induced hemolysis is a common cause of complications during Plasmodium vivax malaria treatment in individuals with glucose 6-phosphate dehydrogenase deficiency (G6PDd). Alternative regimens balancing safety and efficacy are needed.

Methods

G6PDd participants with P. vivax malaria from 2 sites in Brazilian Amazon between 2018 and 2022 were randomly allocated to 3 arms that received chloroquine (CQ) from day 1 to day 3 plus (arm 1) a 7-day course of primaquine (PQ) (0.5 mg/kg/day), beginning at day 5; (arm 2) weekly PQ over 8 weeks (0.75 mg/kg/wk); or (arm 3) weekly CQ over 12 weeks (5 mg/kg/wk). A normal-G6PD participants group was also enrolled in parallel using CQ for 3 days plus PQ for 7 days. The primary focus was safety profile; secondary was

SUBMITTER: Barbosa L 

PROVIDER: S-EPMC12728283 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature